Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Evolus Inc., 3 years.
Evolus Inc.
Director
Tenaya Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −1,900 | $24.92 | $47,348 |
| Jun 15, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −1,899 | $24.62 | $46,753 |
| Apr 16, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +28,895 | — | — |
| Mar 10, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −3,508 | $22.67 | $79,526 |
| Mar 6, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −6,018 | $21.40 | $128,785 |
| Mar 2, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −8,135 | $22.80 | $185,478 |
| Mar 1, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +11,137 | — | — |
| Feb 17, 2026 | Evolus Inc. | Grant or award | +45,559 | — | — |
| Sep 12, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −2,450 | $31.17 | $76,367 |
| Mar 12, 2025 | Evolus Inc. | Open-market sale | −12,888 | $12.99 | $167,415 |
| Mar 7, 2025 | Evolus Inc. | Grant or award | +7,364 | — | — |
| Mar 3, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −12,846 | $42.10 | $540,817 |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +18,443 | — | — |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +14,494 | — | — |
| Feb 27, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −2,230 | $42.93 | $95,734 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.